CryoLife Inc. (NYSE:CRY) shares saw strong trading volume on Thursday . 348,609 shares traded hands during mid-day trading, an increase of 14% from the previous session’s volume of 305,958 shares.The stock last traded at $15.18 and had previously closed at $14.70.

A number of analysts recently weighed in on the stock. Canaccord Genuity reissued a “buy” rating on shares of CryoLife in a report on Tuesday, July 26th. Zacks Investment Research lowered shares of CryoLife from a “buy” rating to a “hold” rating in a report on Wednesday, July 27th. Piper Jaffray Cos. reissued an “overweight” rating and issued a $16.00 price target on shares of CryoLife in a report on Wednesday, July 27th. Ladenburg Thalmann lowered shares of CryoLife from a “buy” rating to a “neutral” rating and set a $12.00 price target for the company. in a report on Thursday, April 28th. They noted that the move was a valuation call. Finally, Lake Street Capital started coverage on shares of CryoLife in a report on Wednesday, June 15th. They issued a “buy” rating and a $15.00 price target for the company. One equities research analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus target price of $15.00.

The firm has a market capitalization of $529.05 million and a PE ratio of 49.71. The company has a 50 day moving average price of $12.97 and a 200-day moving average price of $11.61.

CryoLife (NYSE:CRY) last announced its quarterly earnings results on Monday, July 25th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.02 by $0.11. The business earned $47.10 million during the quarter, compared to analyst estimates of $35.50 million. The company’s revenue was up 32.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.03 earnings per share. On average, equities research analysts forecast that CryoLife Inc. will post $0.24 earnings per share for the current fiscal year.

In other news, Director C Elkins Ronald sold 2,000 shares of the stock in a transaction on Tuesday, July 26th. The shares were sold at an average price of $14.00, for a total transaction of $28,000.00. Following the completion of the sale, the director now directly owns 103,586 shares in the company, valued at $1,450,204. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronald D. Mccall sold 10,000 shares of the stock in a transaction on Wednesday, June 1st. The stock was sold at an average price of $11.56, for a total transaction of $115,600.00. Following the sale, the director now owns 156,248 shares of the company’s stock, valued at $1,806,226.88. The disclosure for this sale can be found here.

An institutional investor recently raised its position in CryoLife stock. Morgan Stanley boosted its stake in CryoLife Inc. (NYSE:CRY) by 1.3% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 1,605,563 shares of the company’s stock after buying an additional 21,067 shares during the period. Morgan Stanley owned approximately 5.64% of CryoLife worth $17,308,000 at the end of the most recent reporting period.

CryoLife, Inc (CryoLife) is engaged in medical device manufacturing and distribution, and in the processing and distribution of implantable human tissues for cardiac and vascular surgeries. The Company operates in two segments: Medical Devices and Preservation Services. The Medical Devices segment sells BioGlue, BioFoam, PerClot, CardioGenesis cardiac laser therapy, Hemodialysis Reliable Outflow (HeRO) Graft, and ProCol Vascular Bioprosthesis (ProCol).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.